Cargando…

Discovery of New Catalytic Topoisomerase II Inhibitors for Anticancer Therapeutics

Poison inhibitors of DNA topoisomerase II (TOP2) are clinically used drugs that cause cancer cell death by inducing DNA damage, which mechanism of action is also associated with serious side effects such as secondary malignancy and cardiotoxicity. In contrast, TOP2 catalytic inhibitors induce limite...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matias-Barrios, Victor M., Radaeva, Mariia, Song, Yi, Alperstein, Zaccary, Lee, Ahn R., Schmitt, Veronika, Lee, Joseph, Ban, Fuqiang, Xie, Ning, Qi, Jianfei, Lallous, Nada, Gleave, Martin E., Cherkasov, Artem, Dong, Xuesen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883873/ https://www.ncbi.nlm.nih.gov/pubmed/33598437 http://dx.doi.org/10.3389/fonc.2020.633142

Ejemplares similares

Optimization of New Catalytic Topoisomerase II Inhibitors as an Anti-Cancer Therapy
por: Matias-Barrios, Victor M., et al.
Publicado: (2021)

Development of Novel Inhibitors Targeting the D-Box of the DNA Binding Domain of Androgen Receptor
por: Radaeva, Mariia, et al.
Publicado: (2021)

Discovery of Novel Lin28 Inhibitors to Suppress Cancer Cell Stemness
por: Radaeva, Mariia, et al.
Publicado: (2022)

PurificationDB: database of purification conditions for proteins
por: Garland, Olivia, et al.
Publicado: (2023)

Lin28 Regulates Cancer Cell Stemness for Tumour Progression
por: Lin, Zhuohui, et al.
Publicado: (2022)

Structure-Based Study to Overcome Cross-Reactivity of Novel Androgen Receptor Inhibitors
por: Radaeva, Mariia, et al.
Publicado: (2022)

Catalytic inhibitors of DNA topoisomerase II suppress the androgen receptor signaling and prostate cancer progression
por: Li, Haolong, et al.
Publicado: (2015)

Dual-Inhibitors of N-Myc and AURKA as Potential Therapy for Neuroendocrine Prostate Cancer
por: Ton, Anh-Tien, et al.
Publicado: (2020)

The Implication of Topoisomerase II Inhibitors in Synthetic Lethality for Cancer Therapy
por: Matias-Barrios, Victor M., et al.
Publicado: (2023)

Targeting Alternative Sites on the Androgen Receptor to Treat Castration-Resistant Prostate Cancer
por: Lallous, Nada, et al.
Publicado: (2013)

Deep Learning Modeling of Androgen Receptor Responses to Prostate Cancer Therapies
por: Snow, Oliver, et al.
Publicado: (2020)

Development of VPC-70619, a Small-Molecule N-Myc Inhibitor as a Potential Therapy for Neuroendocrine Prostate Cancer
por: Ton, Anh-Tien, et al.
Publicado: (2022)

Computer-Aided Discovery of Small Molecules Targeting the RNA Splicing Activity of hnRNP A1 in Castration-Resistant Prostate Cancer
por: Carabet, Lavinia A., et al.
Publicado: (2019)

Deep Docking: A Deep Learning Platform for Augmentation of Structure Based Drug Discovery
por: Gentile, Francesco, et al.
Publicado: (2020)

Phenotypic Discovery of Thiocarbohydrazone with Anticancer Properties and Catalytic Inhibition of Human DNA Topoisomerase IIα
por: Cvijetić, Ilija N., et al.
Publicado: (2023)

Evaluation of Darolutamide (ODM201) Efficiency on Androgen Receptor Mutants Reported to Date in Prostate Cancer Patients
por: Lallous, Nada, et al.
Publicado: (2021)

Ligand Binding Prediction Using Protein Structure Graphs and Residual Graph Attention Networks
por: Pandey, Mohit, et al.
Publicado: (2022)

Computer-Aided Ligand Discovery for Estrogen Receptor Alpha
por: Bafna, Divya, et al.
Publicado: (2020)

20(S)-protopanaxadiol regio-selectively targets androgen receptor: anticancer effects in castration-resistant prostate tumors
por: Ben-Eltriki, Mohamed, et al.
Publicado: (2018)

Development of an Androgen Receptor Inhibitor Targeting the N-Terminal Domain of Androgen Receptor for Treatment of Castration Resistant Prostate Cancer
por: Ban, Fuqiang, et al.
Publicado: (2021)

Acetylation Regulates Thioredoxin Reductase Oligomerization and Activity
por: Wright, David E., et al.
Publicado: (2018)

In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor α
por: Singh, Kriti, et al.
Publicado: (2015)

Benzothiophenone Derivatives Targeting Mutant Forms of Estrogen Receptor-α in Hormone-Resistant Breast Cancers
por: Singh, Kriti, et al.
Publicado: (2018)

SimBoost: a read-across approach for predicting drug–target binding affinities using gradient boosting machines
por: He, Tong, et al.
Publicado: (2017)

DNA topoisomerases as molecular targets for anticancer drugs
por: Buzun, Kamila, et al.
Publicado: (2020)

Automated discovery of noncovalent inhibitors of SARS-CoV-2 main protease by consensus Deep Docking of 40 billion small molecules
por: Gentile, Francesco, et al.
Publicado: (2021)

Regulation of the catalytic function of topoisomerase II alpha through association with RNA
por: Park, Seung-Won, et al.
Publicado: (2008)

Anticancer Activity of Indeno[1,2-b]-Pyridinol Derivative as a New DNA Minor Groove Binding Catalytic Inhibitor of Topoisomerase IIα
por: Jeon, Kyung-Hwa, et al.
Publicado: (2021)

Natural Compounds as Anticancer Agents Targeting DNA Topoisomerases
por: Jain, Chetan Kumar, et al.
Publicado: (2017)

Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients
por: Lallous, Nada, et al.
Publicado: (2016)

Copper Complexes as Anticancer Agents Targeting Topoisomerases I and II
por: Molinaro, Caroline, et al.
Publicado: (2020)

Targeting SARS-CoV-2 papain-like protease in the postvaccine era
por: Ton, Anh-Tien, et al.
Publicado: (2022)

Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin
por: Jong, R S de, et al.
Publicado: (1999)

Non-Catalytic Roles of the Topoisomerase IIα C-Terminal Domain
por: Clarke, Duncan J., et al.
Publicado: (2017)

The MukB-topoisomerase IV interaction mutually suppresses their catalytic activities
por: Kumar, Rupesh, et al.
Publicado: (2021)

DNA-Stimulated Liquid-Liquid phase separation by eukaryotic topoisomerase ii modulates catalytic function
por: Jeong, Joshua, et al.
Publicado: (2022)

Voreloxin Is an Anticancer Quinolone Derivative that Intercalates DNA and Poisons Topoisomerase II
por: Hawtin, Rachael E., et al.
Publicado: (2010)

Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents
por: Cincinelli, Raffaella, et al.
Publicado: (2018)

Exploring DNA Topoisomerase I Ligand Space in Search of Novel Anticancer Agents
por: Drwal, Malgorzata N., et al.
Publicado: (2011)

On the structural basis and design guidelines for type II topoisomerase-targeting anticancer drugs
por: Wu, Chyuan-Chuan, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_s45gpva059dmi8rb1blpc7rk3n